Short answer
Solventum (SOLV) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Solventum reported third-quarter 2026 financial results on November 5, 2026.
Solventum 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Solventum reported third-quarter 2026 financial results on November 5, 2026
- Detailed operating results, financial metrics, and management commentary are in Exhibit 99.1
- Results provide the latest quarterly update on Solventum’s operating performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q3 sales $1.949B, down 7.0% reported and 2.8% organically, reflecting the expected 630 bps ERP-related order reversal
- Adjusted EPS $1.45, down 3.6%, while GAAP EPS fell to $(0.07) from $7.22 due largely to prior-year business-sale gains
- Health Information Systems margin 41.7%, up from 38.8%, offsetting MedSurg margin decline to 16.0% from 16.8%
- Full-year adjusted EPS guidance raised to $7.20 to $7.30, with organic growth expected toward the high end of +2.5% to +3.0%
- ERP cutovers complete and approximately 90% of 3M transition service agreements exited, reducing separation execution risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Solventum 8-K filings
Get the next SOLV 8-K as it lands
Follow SOLV for push alerts, or ask the research agent what this filing means.